Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 2176460, 9 pages
https://doi.org/10.1155/2017/2176460
Research Article

Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients

1Department of Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China
2Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China
3Center of Clinical Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China

Correspondence should be addressed to Xudong Wang; moc.liamtoh@88gnoduxgnaw

Received 5 January 2017; Revised 25 March 2017; Accepted 19 April 2017; Published 8 June 2017

Academic Editor: Andreas Hillenbrand

Copyright © 2017 Can Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Okuda, “Hepatocellular carcinoma,” Journal of Hepatology, vol. 32, 1 Supplement, pp. 225–237, 2000. View at Publisher · View at Google Scholar
  3. S. Mittal and H. B. El-Serag, “Epidemiology of hepatocellular carcinoma: consider the population,” Journal of Clinical Gastroenterology, vol. 47, Supplement 1, pp. S2–S6, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Lin, K. Hoffmann, and P. Schemmer, “Treatment of hepatocellular carcinoma: a systematic review,” Liver Cancer, vol. 1, no. 3-4, pp. 144–158, 2012. View at Publisher · View at Google Scholar
  5. M. Mendizabal and K. R. Reddy, “Current management of hepatocellular carcinoma,” The Medical Clinics of North America, vol. 93, no. 4, pp. 885–900, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. W. Welker and J. Trojan, “Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives,” World Journal of Gastroenterology, vol. 17, no. 26, pp. 3075–3081, 2011. View at Google Scholar
  7. G. M. Keating, “Sorafenib: a review in hepatocellular carcinoma,” Targeted Oncology, vol. 12, no. 2, pp. 243–253, 2017. View at Publisher · View at Google Scholar
  8. Y. J. Chen, C. W. Chi, W. C. Su, and H. L. Huang, “Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma,” Oncotarget, vol. 5, no. 13, pp. 4845–4854, 2014. View at Publisher · View at Google Scholar
  9. S. Tanaka and S. Arii, “Molecular targeted therapies in hepatocellular carcinoma,” Seminars in Oncology, vol. 39, no. 4, pp. 486–492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. L. C. Kapitein, E. J. Peterman, B. H. Kwok, J. H. Kim, T. M. Kapoor, and C. F. Schmidt, “The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks,” Nature, vol. 435, no. 7038, pp. 114–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Shimizu, H. Ishii, N. Ogo et al., “S-trityl-L-cysteine derivative induces caspase-independent cell death in K562 human chronic myeloid leukemia cell line,” Cancer Letters, vol. 298, no. 1, pp. 99–106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Yang, C. Jiang, F. Liu, Q. D. You, and W. T. Wu, “Cloning, enzyme characterization of recombinant human Eg5 and the development of a new inhibitor,” Biological & Pharmaceutical Bulletin, vol. 31, no. 7, pp. 1397–1402, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Saijo, G. Ishii, A. Ochiai et al., “Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy,” Lung Cancer, vol. 54, no. 2, pp. 217–225, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Liu, X. Wang, Y. Yang et al., “Ectopic expression of the microtubule-dependent motor protein Eg5 promotes pancreatic tumourigenesis,” The Journal of Pathology, vol. 221, no. 2, pp. 221–228, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. G. R. Yan, F. Y. Zou, B. L. Dang et al., “Genistein-induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study,” Proteomics, vol. 12, no. 14, pp. 2391–2399, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Nakai, S. Iida, T. Takahashi et al., “K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells,” Cancer Research, vol. 69, no. 9, pp. 3901–3909, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. D. Wissing, E. S. De Morree, V. O. Dezentje et al., “Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness,” Oncotarget, vol. 5, no. 17, pp. 7357–7367, 2014. View at Publisher · View at Google Scholar
  18. T. U. Mayer, T. M. Kapoor, S. J. Haggarty, R. W. King, S. L. Schreiber, and T. J. Mitchison, “Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen,” Science, vol. 286, no. 5441, pp. 971–974, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Ding, K. Nishizawa, T. Kobayashi et al., “A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor,” The Journal of Urology, vol. 184, no. 3, pp. 1175–1181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Tao, V. J. South, R. E. Diehl et al., “An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis,” Molecular and Cellular Biology, vol. 27, no. 2, pp. 689–698, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. S. R. Hamilton and L. A. Aaltonen, “Pathology and genetics of tumours of the digestive system,” World Health Organization Classification of Tumours (WHO OMS), IARC Press, Lyon, 2000. View at Google Scholar
  22. J. Huang, H. Zhu, X. Wang et al., “The patterns and expression of KDR in normal tissues of human internal organs,” Journal of Molecular Histology, vol. 42, no. 6, pp. 597–603, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Lu, H. Zhu, X. Wang et al., “The prognostic role of Eg5 expression in laryngeal squamous cell carcinoma,” Pathology, vol. 48, no. 3, pp. 214–218, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Huang, X. Zhang, Q. Tang et al., “Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma,” Journal of Clinical Pathology, vol. 64, no. 4, pp. 343–348, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. K. W. Wood, W. D. Cornwell, and J. R. Jackson, “Past and future of the mitotic spindle as an oncology target,” Current Opinion in Pharmacology, vol. 1, no. 4, pp. 370–377, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. X. Liu, H. Gong, and K. Huang, “Oncogenic role of kinesin proteins and targeting kinesin therapy,” Cancer Science, vol. 104, no. 6, pp. 651–656, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Liu, D. Li, L. Sun et al., “Modulation of Eg5 activity contributes to mitotic spindle checkpoint activation and Tat-mediated apoptosis in CD4-positive T-lymphocytes,” The Journal of Pathology, vol. 233, no. 2, pp. 138–147, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Groth-Pedersen, S. Aits, E. Corcelle-Termeau, N. H. Petersen, J. Nylandsted, and M. Jaattela, “Identification of cytoskeleton-associated proteins essential for lysosomal stability and survival of human cancer cells,” PloS One, vol. 7, no. 10, article e45381, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. K. M. Bartoli, J. Jakovljevic, J. J. Woolford, and W. S. Saunders, “Kinesin molecular motor Eg5 functions during polypeptide synthesis,” Molecular Biology of the Cell, vol. 22, no. 18, pp. 3420–3430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Midorikawa, Y. Takei, and N. Hirokawa, “KIF4 motor regulates activity-dependent neuronal survival by suppressing PARP-1 enzymatic activity,” Cell, vol. 125, no. 2, pp. 371–383, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Falnikar, S. Tole, and P. W. Baas, “Kinesin-5, a mitotic microtubule-associated motor protein, modulates neuronal migration,” Molecular Biology of the Cell, vol. 22, no. 9, pp. 1561–1574, 2011. View at Google Scholar
  32. X. D. Sun, X. J. Shi, X. O. Sun et al., “Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5,” Acta Pharmacologica Sinica, vol. 32, no. 12, pp. 1543–1548, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Exertier, S. Javerzat, B. Wang et al., “Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5,” Oncotarget, vol. 4, no. 12, pp. 2302–2316, 2013. View at Publisher · View at Google Scholar
  34. D. Sun, J. Lu, K. Ding et al., “The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma,” Medical Oncology, vol. 30, no. 1, p. 476, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Ding, N. Xing, J. Lu et al., “Overexpression of Eg5 predicts unfavorable prognosis in non-muscle invasive bladder urothelial carcinoma,” International Journal of Urology, vol. 18, no. 6, pp. 432–438, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Yang, M. Fu, Y. Ding et al., “High SHIP2 expression indicates poor survival in colorectal cancer,” Disease Markers, vol. 2014, Article ID 218968, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus